Mendus to participate in upcoming conferences in April 2023 and to hold investor call following Annual Report publication on April 17th

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:


Innovation for Health

Rotterdam, The Netherlands, April 6, 2023

Erik Manting, CEO of Mendus, will be part of a panel discussion on partnerships and deal-making.

https://www.hyphenprojects.nl/i4h


AACR Annual Meeting 2023

Orlando, FL, USA, April 14–19, 2023

Mendus to present interim data from the ALISON trial in ovarian cancer.

https://www.aacr.org/meeting/aacr-annual-meeting-2023/


Kempen’s 14th Life Sciences Conference

Amsterdam, The Netherlands, April 25-26, 2023

Mendus’ leadership team will participate and Erik Manting, CEO of Mendus, will give a presentation at the conference.

https://www.vanlanschotkempen.com/en-nl/investment-banking/equities/life-sciences-and-healthcare/life-sciences-conference 

Additionally, Mendus will host an online event for shareholders on April 17, in conjunction with the publication of the company’s Annual Report 2022.


Online event in conjunction with the publication of the Annual Report 2022

Date: 17 April 2023

Time: 10.00 – 10.30 CET

Registration via the registration link: https://edge.media-server.com/mmc/p/upb3kyua

A replay of the webcast will be available via the corporate website following the live event.


FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com


INVESTOR RELATIONS
Corey Davis

LifeSci Advisors, LLC

Telephone: + 1 212-915-2577

E-mail: cdavis@lifesciadvisors.com


MEDIA RELATIONS
Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu


ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

Attachment

Staff

Recent Posts

ECOSEP and Tata Elxsi Announce Strategic Partnership to Transform Sports Medicine through AI

BENGALURU, India, May 7, 2025 /PRNewswire/ -- European College of Sport and Exercise Physicians (ECOSEP) and…

2 hours ago

Grant Industries Selects Labbit LIMS to Drive Digital Transformation Across Its Regulated Labs

Labbit's graph-based architecture supports the unique needs of Grant's different lab environments while unifying data…

2 hours ago

The Future of Ultrasound Reporting 

By Cecile Brosset, CEO of Sonio The landscape of ultrasound technology is rapidly evolving, driven…

20 hours ago

Beyond Medical Technologies Announces $2.5 Million Convertible Note Financing to Support Blockchain Attestation Platform

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…

20 hours ago

Albert Einstein College of Medicine Launches Data Science Institute

Leveraging the Power of Data to Accelerate Scientific Discovery and Improve Health in the Bronx…

20 hours ago

Plasmidsaurus Opens 10th Global Lab in Singapore, Scaling to Meet the Demand for Cutting-Edge Sequencing Around the World

SINGAPORE and SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Plasmidsaurus, the company that…

20 hours ago